Bimodal Ondansetron Pill Eases Vomiting in Gastroenteritis Bimodal Ondansetron Pill Eases Vomiting in Gastroenteritis
A single long-acting tablet prevented vomiting for significantly longer than traditional medication in most recipients, a study found.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - November 11, 2019 Category: Internal Medicine Tags: Internal Medicine News Source Type: news
Ondansetron (Zofran) vs. promethazine (Phenergan)
Title: Ondansetron (Zofran) vs. promethazine (Phenergan)Category: MedicationsCreated: 7/29/2019 12:00:00 AMLast Editorial Review: 7/29/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - July 29, 2019 Category: Drugs & Pharmacology Source Type: news
Ondansetron (Zofran) vs. palonosetron (Aloxi)
Title: Ondansetron (Zofran) vs. palonosetron (Aloxi)Category: MedicationsCreated: 7/29/2019 12:00:00 AMLast Editorial Review: 7/29/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - July 29, 2019 Category: Drugs & Pharmacology Source Type: news
Ondansetron (Zofran) vs. metoclopramide (Reglan)
Title: Ondansetron (Zofran) vs. metoclopramide (Reglan)Category: MedicationsCreated: 7/26/2019 12:00:00 AMLast Editorial Review: 7/26/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - July 26, 2019 Category: Drugs & Pharmacology Source Type: news
Fresenius Kabi Issues Voluntary Nationwide Recall of Midazolam Injection, USP, 2 mg/2 mL Due to Reports of Blister Packages Containing Syringes of Ondansetron Injection, USP, 4 mg/2 mL
Fresenius Kabi USA is voluntarily recalling Lot 6400048 of Midazolam Injection, USP, 2 mg/2 mL packaged in a 2 mL prefilled single-use glass syringe to the hospital/user level. The product mislabeled as Midazolam Injection,
USP, 2 mg/2 mL contains syringes containing and labeled as Ondansetron Injection, USP, 4 mg/2 mL. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 25, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Ondansetron (Zofran) vs. meclizine
Title: Ondansetron (Zofran) vs. meclizineCategory: MedicationsCreated: 7/25/2019 12:00:00 AMLast Editorial Review: 7/25/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - July 25, 2019 Category: Drugs & Pharmacology Source Type: news
Ondansetron (Zofran) vs. Dramamine
Title: Ondansetron (Zofran) vs. DramamineCategory: MedicationsCreated: 7/24/2019 12:00:00 AMLast Editorial Review: 7/24/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - July 24, 2019 Category: Drugs & Pharmacology Source Type: news
Ondansetron (Zofran) vs. alosetron (Lotronex)
Title: Ondansetron (Zofran) vs. alosetron (Lotronex)Category: MedicationsCreated: 7/23/2019 12:00:00 AMLast Editorial Review: 7/23/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - July 23, 2019 Category: Drugs & Pharmacology Source Type: news
ondansetron (Zofran, Zofran ODT, Zuplenz)
Title: ondansetron (Zofran, Zofran ODT, Zuplenz)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 7/2/2019 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 2, 2019 Category: Cancer & Oncology Source Type: news
FDA Drug Safety Communication: Abnormal heart rhythms may be associated with use of Zofran (ondansetron)
[09-15-2011] The U.S. Food and Drug Administration (FDA) is informing the public of an ongoing safety review of the anti-nausea drug Zofran (ondansetron, ondansetron hydrochloride and their generics). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 28, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Drug Safety Communication: Updated information on 32 mg intravenous ondansetron (Zofran) dose and pre-mixed ondansetron products
The U.S. Food and Drug Administration (FDA) is notifying health care professionals that the 32 mg, single intravenous (IV) dose of the antinausea drug Zofran (ondansetron hydrochloride) will no longer be marketed because of the potential for serious cardiac risks. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 26, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
The Mushroom Chronicles: The Case of the Poisonous Omelet
On a summer afternoon in suburban Virginia, one BLS and two ALS ambulances are dispatched to an apartment complex for three people experiencing severe abdominal pain with nausea, vomiting and diarrhea onset three hours ago.
Dispatch states that the patients picked, cooked and ate mushrooms from their neighborhood courtyard around 10:00 a.m. The family is from out of the country; mother and father are in their sixties and a son who is in his thirties. They said they picked the mushrooms and cooked them in an omelet, and that after breakfast, each of them became ill. Symptoms started with severe abdominal pain, followed by n...
Source: JEMS Patient Care - May 3, 2019 Category: Emergency Medicine Authors: Jennifer Rabjohns, MFA, MD Tags: Exclusive Articles Patient Care Top Story Source Type: news
What to D.O.: Relegate Ondansetron to Auxiliary Role in Pregnancy
No abstract available (Source: Emergency Medicine News)
Source: Emergency Medicine News - March 1, 2019 Category: Emergency Medicine Tags: What to D.O. Source Type: news
Not Just Acid Reflux: The Need to Think Worst First
Discussion
Heart disease is the leading cause of death in the United States.1 This year, 720,000 Americans will have a new coronary event—defined as first hospitalized myocardial infarction (MI) or coronary heart disease death—and around 335,000 will have a recurrent event. Approximately 35% of people who experience a coronary event in a given year and around 14% of patients who have an acute coronary syndrome will die from it.1 Roughly 60% of patients with an acute coronary syndrome are transported to the emergency department via ambulance.2–4.
Up to one-third of patients experiencing an MI may not complain of chest...
Source: JEMS Special Topics - January 13, 2019 Category: Emergency Medicine Authors: Stephen Sanko, MD, FACEP Tags: Exclusive Articles Cardiac & Resuscitation Source Type: news
Study: Ondansetron Mostly Safe in Early Pregnancy
(MedPage Today) -- Increased risk of oral clefts and ear malformations, however (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - December 19, 2018 Category: Gastroenterology Source Type: news
